Latest studies
Every paper our editors flag with a plain-language note and an evidence rating. Filter by evidence, species, or design to find what actually applies to you.
- Study · MOTS-cSupported
Mitochondria-derived peptide hydrogel augments mitochondrial transplantation for promoting cardiac repair via macrophage metabolic reprogramming.
A materials-science paper where MOTS-c is doing real mechanistic work — the AMPK-dependent uptake step and the glycolysis-to-OXPHOS shift in macrophages are both characterised, not assumed. Limits are stage-appropriate: a rat myocardial-infarction model, functional readouts over a short window, and no way to attribute the benefit to MOTS-c alone versus the mitochondria it delivers. Nothing here speaks to systemic or injected MOTS-c as used outside a lab. Read it as early evidence for a delivery platform.
Bioactive materialsn=—AnimalJan 1, 2027 - Study · MOTS-cWeak / none
Mitochondrial-derived peptides (MDPs) activated by physical exercise as therapeutic targets for metabolic disorders: A systematic review.
Nine heterogeneous studies is a narrow base, and the review reports a direction of effect rather than a pooled estimate; there is no meta-analysis and no formal risk-of-bias synthesis in the abstract. The MOTS-c literature still leans heavily on animal and mechanistic work, so the human exercise signal is suggestive at best. It is also worth separating two propositions that this paper tends to blur: that exercise raises endogenous MOTS-c is a different claim from anything about administered MOTS-c, which the review does not examine.
Physiology internationaln=——Aug 25, 2026 - Study · MOTS-cWeak / none
MOTS-c in sepsis-induced cardiomyopathy: Mechanisms and translational potential.
An unusually disciplined review: the authors explicitly separate findings generated in sepsis-induced cardiomyopathy models from those extrapolated from other cardiovascular and metabolic settings, which is precisely the distinction most MOTS-c writing blurs. Their conclusion is that MOTS-c is plausible but insufficiently validated here, and they flag biomarker specificity and biodistribution under septic conditions as open problems. No human data, no dosing, no efficacy claim. Worth logging for readers following MOTS-c as a mitochondrial-stress signal rather than as anything clinically actionable.
European journal of pharmacologyn=——Aug 23, 2026 - Study · MOTS-cSupported
MOTS-c is a mitochondrial-encoded interferon-linked host defense peptide.
This is careful mechanistic work in cells and mice from the Lee lab, and it reframes MOTS-c as an immune factor rather than a purely metabolic one, which is a genuinely new claim about mitochondrial genome function. The antibacterial and macrophage-programming results are preclinical, at doses and routes that say nothing about what subcutaneous use in humans would do. For readers following MOTS-c, the value is in the mechanism and the interferon link, not in any clinical implication.
eLifen=—AnimalAug 18, 2026 - Study · MOTS-cWeak / none
MOTS-c attenuates hyperoxia-induced neonatal cardiac injury by inhibiting oxeiptosis via maintaining the KEAP1-PGAM5 interaction.
In neonatal mice and a rat cardiomyocyte line exposed to high oxygen (hyperoxia), researchers found that MOTS-c lessened oxidative cardiac injury, and that serum MOTS-c fell with hyperoxia. They attribute the protection to inhibition of oxeiptosis, a reactive-oxygen-driven form of cell death, via preservation of the KEAP1-PGAM5 interaction; forcing KEAP1 expression abolished the benefit, supporting KEAP1 as the target. This is a mechanistic, single-model preclinical study. These are preclinical findings; human data are needed before any clinical conclusions can be drawn, and the term "therapeutic agent" in the abstract reflects the authors' framing, not demonstrated clinical benefit. It is consistent with MOTS-c's recurring antioxidant, mitochondria-protective role in animal tissue-injury models.
Life sciencesn=—AnimalAug 1, 2026 - Study · MOTS-cWeak / none
Mitochondrial-derived peptide MOTS-c targets SLC7A11 to preserve spermatogenesis by suppressing ferroptosis.
A preclinical study on MOTS-c and sperm production. The authors report that serum MOTS-c was lower in men with oligoasthenozoospermia and correlated with semen quality, then used a mouse mechanical-stress (microgravity) model to show spermatogenic impairment. Exogenous MOTS-c was associated with reduced oxidative stress and ferroptosis and better-preserved spermatogenesis, with SLC7A11 identified as a molecular target through loss- and gain-of-function experiments. These are preclinical findings plus a human correlation; human interventional data are needed before clinical conclusions can be drawn. Key caveats: the human component is observational and correlational (low MOTS-c associates with poorer semen quality, which does not establish direction or cause), and the therapeutic effect is demonstrated only in a mouse stress model. For a tracked peptide this is a mechanistically detailed but early signal for MOTS-c in male fertility, hypothesis-generating, not clinical evidence.
Free radical biology & medicinen=—AnimalJul 1, 2026 - Study · MOTS-cWeak / none
LAT1-mediated delivery of engineered R13A-MOTS-c attenuates radiation-induced lung injury via Nrf2 activation and mitochondrial protection.
A preclinical study engineering a modified MOTS-c (R13A-MOTS-c) to improve cell uptake, then testing it against radiation-induced lung injury. In cells and in C57BL/6 mice given thoracic irradiation, daily intraperitoneal R13A-MOTS-c (5 mg/kg for two weeks) was associated with reduced lung inflammation, oxidative stress and mitochondrial dysfunction, with effects tied to activation of the Nrf2 antioxidant pathway and lost when Nrf2 or the LAT1 transporter were blocked. These are preclinical findings; human data are needed before clinical conclusions can be drawn. Two specifics matter for readers: the agent is an engineered analog, not native MOTS-c, so results may not transfer to the unmodified peptide, and the model is acute radiation injury in mice. This is a mechanistically detailed signal for MOTS-c-based approaches, useful as hypothesis-generating context, not evidence of benefit in people.
Redox biologyn=—AnimalJul 1, 2026 - Study · MOTS-cMixed
Mitochondrial-derived peptide MOTS-c activates metabolic signaling but blunts reparative function in human mesenchymal stromal cells.
This is a notable counter-signal study on MOTS-c, the mitochondrial-derived peptide often framed as an exercise-mimetic metabolic regulator. Using adipose-derived mesenchymal stromal cells from people with obesity and lean donors, plus a mouse kidney-stenosis model, researchers reported that exogenous MOTS-c did activate AMPK signaling but paradoxically reduced cell proliferation, increased senescence markers (p16, p21) and TNF-alpha, and, in vivo, failed to improve kidney perfusion, fibrosis or injury, while also blunting the reparative efficacy of lean-donor cells. The message is that metabolic activation did not translate to improved regenerative function and may have worsened senescence and inflammation. It is preclinical (human cells plus mouse model), but a well-constructed cautionary data point against assuming MOTS-c is uniformly beneficial. These are preclinical findings; human data are needed before clinical conclusions can be drawn.
Inflammation and regenerationn=—AnimalJun 22, 2026 - Study · MOTS-cWeak / none
Mitochondrial peptide MOTS-c suppresses systemic and cardiac inflammasome activation in a diabetic rat model.
In a high-fat-diet/streptozotocin rat model of type-2 diabetes, researchers reported that MOTS-c treatment lowered fasting blood glucose and C-reactive protein, modulated inflammatory cytokines (IL-10, IL-1beta), and reduced NLRP3-inflammasome components (NLRP3, ASC, cleaved caspase-1) in heart tissue. They frame this as MOTS-c dampening systemic and cardiac inflammation relevant to diabetic cardiomyopathy. It is a single preclinical rodent study with biochemical and immunohistochemical endpoints, mechanistically consistent with MOTS-c's proposed metabolic and anti-inflammatory roles but far from clinical proof, and it should be read alongside the counter-signal stromal-cell study in this batch showing context-dependent effects. These are preclinical findings; human data are needed before clinical conclusions can be drawn.
Experimental physiologyn=—AnimalJun 19, 2026 - Study · MOTS-cWeak / none
MOTS-c, a mitochondrial-derived peptide, ameliorates lysosomal membrane permeability and improves survival of soft tissue transplantation.
In an animal ischemic-flap model, researchers report that MOTS-c improved blood perfusion and tissue survival, reducing endothelial cell death (pyroptosis), enhancing autophagy, and limiting lysosomal membrane damage. Mechanistically they trace the effect to suppression of PLA2G4A via a MAPK-NF-kB cascade, supported by gene-overexpression experiments. This is a mechanism-heavy, single-model preclinical study; it establishes plausible pathways, not clinical benefit. These are preclinical findings, and human data would be needed before any conclusions about reconstructive surgery could be drawn. It fits the broader MOTS-c pattern of protecting stressed tissue by stabilising mitochondrial and lysosomal function, but the specificity of the proposed PLA2G4A axis rests on this one dataset and warrants independent replication.
Autophagyn=—AnimalJun 2, 2026 - Study · MOTS-cWeak / none
MOTS-c preserves mitochondrial subpopulation bioenergetics and genome integrity to attenuate cardiac ischemia reperfusion injury.
In an isolated (Langendorff-perfused) rat heart model, researchers found that MOTS-c, given before ischaemia or at reperfusion, improved post-ischaemic mechanical recovery and partly preserved mitochondrial function after ischaemia-reperfusion injury. The design is mechanistic and ex vivo: female Wistar rat hearts, six per group, studied outside the body, so systemic and long-term effects are not captured. Effects varied across mitochondrial subpopulations and parameters, and the authors note the signalling mechanism still needs validation. These are preclinical findings; human data are needed before any clinical conclusions can be drawn. The result is consistent with a recurring MOTS-c theme, cardioprotection against ischaemic and oxidative stress in animal hearts, but replication in small isolated-organ models does not substitute for controlled human trials, of which there are none for exogenous MOTS-c.
Molecular biology reportsn=—AnimalJun 2, 2026